Advertisement
Australia markets closed

  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     

  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     

  • AUD/USD

    0.6604
    -0.0017 (-0.26%)
     

  • OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD

    2,366.90
    +26.60 (+1.14%)
     

  • Bitcoin AUD

    91,887.54
    -3,022.91 (-3.19%)
     

  • CMC Crypto 200

    1,258.75
    -99.26 (-7.31%)
     

  • AUD/EUR

    0.6128
    -0.0010 (-0.16%)
     

  • AUD/NZD

    1.0963
    -0.0006 (-0.05%)
     

  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     

  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021

Cybrexa Therapeutics
·2-min read

NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that management is scheduled to deliver a company presentation at BTIG Virtual Biotechnology Conference 2021 on Monday, August 9th at 9:00 am ET. The team will also host one-on-one investor meetings throughout the conference.

Per Hellsund, President and CEO of Cybrexa, will provide an overview of CBX-12 (alphalex™-exatecan), the company’s lead therapeutic candidate for solid tumors, and the recently initiated Phase 1/2 trial in patients with advanced or metastatic refractory solid tumors. CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™. In contrast to these ADCs, CBX-12 is able to target cancer cells independent of antigen expression, which could greatly expand the addressable patient populations.

About the alphalex™ Technology Platform
The Cybrexa alphalex™ technology platform – which consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent (payload) – enables antigen-independent targeting of tumors and intracellular delivery of highly potent anticancer therapies, creating therapeutics that can revolutionize the standard of care. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. View a video of the mechanism of action of the technology at www.cybrexa.com.

About Cybrexa
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, has entered a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more information about Cybrexa, please visit www.cybrexa.com.

ADVERTISEMENT

Contacts

Cybrexa Therapeutics
Lisa Rehm
Email: lisa.rehm@cybrexa.com

Westwicke, an ICR Company
Investor Relations
Stephanie Carrington
Tel: 646-277-1282
Email: Stephanie.Carrington@westwicke.com

Media Relations
Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@westwicke.com